Zobrazeno 1 - 9
of 9
pro vyhledávání: '"O. V. Sema"'
Publikováno v:
Chernivtsi University Scientific Herald. Chemistry. :35-41
The results of the spectral, electrochemical and energy characteristics of symmetric cationic polymethine dye 2 - [(1E) -1,3,5-hexatrienyl -] - 1- (phenylmethyl)-benzindolium boron fluoride (D) indicate the possibility of its use as an effective tita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33b1f5e19f51e175414fa7347aa6a938
https://doi.org/10.31861/chem-2019-818-05
https://doi.org/10.31861/chem-2019-818-05
Publikováno v:
Chernivtsi University Scientific Herald. Chemistry. :17-22
On the basis of nanodispersed titanium(IV) oxide and squaraine dye-sensitizer (D), new heterostructures (HS) have been created with a given level of photocatalytic activity and an expanded range of photosensitivity. On the basis of the analysis of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::935a682385230bc82ad72f6508641c02
https://doi.org/10.31861/chem-2019-819-03
https://doi.org/10.31861/chem-2019-819-03
Autor:
A. E. Karateev, Yu. V. Barysheva, Ya. V. Belokon, T. Yu. Bolshakova, Yu. Yu. Grabovetskaya, E. A. Dolzhenkova, L. N. Eliseeva, O. B. Ershova, E. V. Zonova, I. Yu. Chernova, A. O. Isakanova, M. N. Kirpikova, V. T. Komarov, E. V. Kryukova, A. I. Kulikov, D. I. Lakhin, L. A. Levasheva, L. V. Masneva, L. V. Menshikova, Yu. V. Mishina, S. V. Norina, Yu. N. Pashkovsky, A. V. Petrov, A. G. Rusanov, A. V. Sarapulova, K. A. Svodtseva, O. V. Semagina, A. N. Sudakova, S. N. Tkachenko, M. M. Toporkov, S. K. Tutelyan, G. R. Fadienko, O. S. Filonenko, O. P. Fomina, A. S. Chernov
Publikováno v:
Современная ревматология, Vol 14, Iss 4, Pp 82-90 (2020)
A combination of chondroitin and glucosamine is widely used in clinical practice as both a symptomatic and structure-modifying agent for the treatment of osteoarthritis (OA). The emergence of new drugs based on this combination substantially expands
Externí odkaz:
https://doaj.org/article/913187d83c914518970f41838708eadd
Autor:
A. E. Karateev, E. S. Filatova, E. Yu. Pogozheva, V. N. Amirdzhanova, E. L. Nasonov, A. M. Lila, V. I. Mazurov, A. Yu. De, A. A. Baranov, N. A. Lapkina, G. V. Lukina, N. A. Kiryukhina, S. Yu. Davidyan, T. S. Salnikova, R. R. Samigullina, D. S. Chakieva, I. M. Marusenko, O. V. Semagina, M. Yu. Semchenkova, A. F. Davydova, E. V. Kalinina
Publikováno v:
Современная ревматология, Vol 14, Iss 2, Pp 69-75 (2020)
Janus kinase (JK) inhibitors block the intracellular signaling pathways that are responsible for the synthesis of proinflammatory cytokines and mediators, which in turn cause the activation of pain receptors and central sensitization (CS). It is sugg
Externí odkaz:
https://doaj.org/article/af84c1d6e4e34c688e41f9ab87acd8f6
Autor:
A. E. Karateev, E. Yu. Pogozheva, V. N. Amirjanova, E. S. Filatova, A. M. Lila, V. I. Mazurov, R. R. Samigullina, A. M. Dadalova, A. Yu. Dyo, D. S. Chakieva, A. A. Baranov, N. A. Lapkina, E. N. Koltsova, N. A. Kiryukhina, I. N. Shchendrigin, T. G. Rasevich, A. F. Davydova, I. V. Semizarova, I. A. Shafieva, I. B. Bashkova, D. A. Bobrikova, D. A. Murtazalieva, I. N. Kushnir, E. V. Kalinina, T. S. Salnikova, I. M. Marusenko, O. V. Semagina, I. B. Vinogradova, D. G. Krechikova, M. Yu. Semchenkova, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 59, Iss 4 (2021)
The JAK inhibitor tofacitinib (TOFA) blocks the intracellular signaling pathway that activates the synthesis of cytokines and mediators involved in the development of pain and central sensitization (CS), which determines the rapid analgesic effect. H
Externí odkaz:
https://doaj.org/article/f878a9466c984864885b3baf4937c75e
Autor:
D. E. Karateev, D. E. Abdulganieva, A. R. Babaeva, A. A. Baranov, L. P. Evstigneeva, O. N. Ivanova, G. V. Lukina, E. L. Luchikhina, V. I. Mazurov, A. S. Misiyuk, O. V. Semagina, A. E. Sizikov, V. N. Sorotskaya
Publikováno v:
Современная ревматология, Vol 11, Iss 1, Pp 12-18 (2017)
Tofacitinib (TOFA), a representative of a new class of targeted synthetic disease-modifying antirheumatic drugs (s-DMARD), is a promising drug for treating rheumatoid arthritis (RA) and other immune inflammatory diseases.Objective: to evaluate the ef
Externí odkaz:
https://doaj.org/article/839287e5b05248d6961f1e62357d6a26
Autor:
D. E. Karateev, D. E. Abdulganieva, A. R. Babaeva, A. A. Baranov, L. P. Evstigneeva, O. N. Ivanova, G. V. Lukina, E. L. Luchikhina, V. I. Mazurov, A. S. Misiyuk, O. V. Semagina, A. E. Sizikov, V. N. Sorotskaya
Publikováno v:
Современная ревматология, Vol 10, Iss 3, Pp 52-61 (2016)
Tofacitinib (TOFA), a member of a new class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), is a promising medication for the treatment of rheumatoid arthritis (RA) and other immunoinflammatory diseases. The paper describes the
Externí odkaz:
https://doaj.org/article/59fa1f3746ae4a15b40752fe3b17240e
Autor:
R. M. Balabanova, T. V. Dubinina, D. V. Goryachev, O. N. Anoshenkova, E. A. Antonova, I. Yu. Ilyevsky, O. V. Semagina, N. V. Yasyukevih
Publikováno v:
Современная ревматология, Vol 9, Iss 2, Pp 33-36 (2015)
Methotrexate or leflunomide is used as a first-line synthetic disease-modifying anti-rheumatic drug in the therapy of rheumatoid arthritis (RA). In 2011, the Russian Federation registered and since it has been successfully using leflunomide**.Objecti
Externí odkaz:
https://doaj.org/article/2266c3b07aa0428a9b22881652d4ff02
Autor:
O. V. Semagina, V A Rossiev
Publikováno v:
Научно-практическая ревматология, Vol 38, Iss 4 (2000)
Externí odkaz:
https://doaj.org/article/fadb9f9bb2d84f8b85e6e8e6dd2778fb